Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer

British Journal of Cancer

Volumn 99, Issue 12, 2008, Pages 1984-1990

  Cameron, D A ^a   Camidge, D R ^b   Oyee, J ^c   Hirsch, M ^d  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c MAPI VALUES   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Advanced breast cancer; Cost effectiveness; Faslodex; Fulvestrant; Hormone receptor positive

Indexed keywords

ANASTROZOLE; CAPECITABINE; DOCETAXEL; EXEMESTANE; FULVESTRANT; LETROZOLE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ESTRADIOL; HORMONE REPLACEMENT THERAPY; HUMANS; NEOPLASM STAGING; RECEPTORS, ESTROGEN; SUBSTRATE SPECIFICITY;

EID: 57449109487     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604790     Document Type: Article

References (35)

1. American Cancer society, ACS (2006) (2006) What Are the Key Statistics for Breast Cancer? http://www.cancer.org/docroot/CRI/content/ CRI_2_4_1X_What_are_the_key_statistics_for_breast_cancer_5.asp
2. Bertelli G, Paridaens R (2006) Optimal sequence of hormonotherapy in advanced breast cancer. Curr Opin Oncol 18: 572-577
3. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92: 1759-1768
4. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493
5. Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13: 397-409
6. British National Formulary (BNF) (2006) http://www.bnf.org/bnf/
7. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C (2001) Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer vs megestrol acetate. J Clin Oncol 19(14): 3357-3366
8. Cancer Research UK (2005) UK Breast Cancer statistics, http://info.cancerresearchuk.org/cancerstats/types/breast/?a=5441
9. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil GM, Bodrogi I, Murray E, Yelle L, Von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez MR, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial of docetaxel vs doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354
10. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26: 1664-1670
11. Curtis L, Netten A (2005) Unit Costs of Health and Social Care 2005, Personal Social Services Research Unit (PSSRU). University of Kent: Canterbury http://www.pssru.ac.uk/uc/uc2005contents.htm
12. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controlled Clin Trials 7(3): 177-188
13. Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, Morris R, Price M (2006) Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17: 205-210
14. Gradishar W, Chia S, Piccart M, on behalf of the EFECT writing committeeyRobert HLurie (2007) Fulvestrant vs exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 104: 231. DOI:10.1007/s10549-007-9661-1
15. Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF (2005) Fulvestrant vs anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104: 236-239
16. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK (2004) Comparison of fulvestrant vs tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605-1613
17. Howell A, Robertson JF, Quaresma AJ, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002) Fulvestrant, formerly ICI 182 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403
18. Hutton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A (1996) A new decision model for cost-utility comparisons of chemotherapy in breast cancer. Pharmacoeconomics 9: 8-22
19. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA (2006) Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24: 1052-1056
20. Laffaioli RV, Formato R, Tortoriello A, Del Prete S, Caraglia M, Pappagallo G, Pisano A, Gebbia V, Fanelli F, Ianniello G, Cigolari S, Pizza C, Marano O, Pezzella G, Pedicini T, Febbraro A, Incoronato P, Manzione L, Ferrari E, Marzano N, Quattrin S, Pisconti S, Nasti G, Giotta G, Colucci G, Southern Italy Oncology Group (2005) Southern Italy Oncology Group. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer 2005 92(9): 1621-1625 Erratum in: Br J Cancer 2005 Sep 5;93(5):611
21. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O, Howell A (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67: 111-116
22. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21: 968-975
23. National Institute for Clinical Excellence (NICE) (2006) Clinical guidance; Advanced breast cancer: diagnosis and treatment. NICE: London (UK) http://www.nice.org.uk/page.aspx?o=395068
24. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823
25. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant vs anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386-3395
26. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S (2006) Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 24: 355-371
27. Rawlins MD, Culyer AJ (2004) National Institute for Clinical Excellence and its value judgments. BMJ 329: 224-227
28. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C (2003) Fulvestrant vs anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98: 229-238
29. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ben Ayed F, Burdette-Radoux S, Chaudri-Ross HA, Lang R (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39: 2318-2327
30. Scottish Intercollegiate Guidelines Network (SIGN) (2005) Management of breast cancer in women A national clinical guideline. Scottish Intercollegiate Guidelines Network (SIGN): Edinburgh (Scotland). 50 p. (SIGN publication; no. 84)
31. Steger GG, Gips M, Simon SD, Lluch A, Vinholes J, Kaufman B, Wardley A, Mauriac L (2005) Fulvestrant ('Faslodex'): clinical experience from the Compassionate Use Programme. Cancer Treat Rev 31(Suppl 2): S10-S16
32. Thurlimann B, Hess D, Koberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A (2004) Anastrozole ('Arimidex') vs tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over trial 21/95-a substudy of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability). Breast Cancer Res Treat 85: 247-254
33. Tobias JS (2004) Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. Ann Oncol 15: 1738-1747
34. Tominaga T, Adachi I, Sasaki Y, Tabei T, Ikeda T, Takatsuka Y, Toi M, Suwa T, Ohashi Y (2002) Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. Ann Oncol 14: 62-70
35. Vergote I, Robertson JF, Kleeberg U, Burton G, Osborne CK, Mauriac L (2003) Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 79: 207-211